BEDFORD, Mass., May 31, 2017 — Homology Medicines, Inc., a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients, announced today the appointment of Tim Kelly as Senior Vice President, Technical Operations. Mr. Kelly brings more than 20 years of global product development and manufacturing experience to Homology encompassing preclinical to commercialization with a focus on rare disease therapies and biologics.
“Tim is a seasoned pharmaceutical executive with unparalleled expertise building and growing industry-leading global technical operations and CMC functions,” said Arthur Tzianabos, Ph.D., Chief Executive Officer of Homology Medicines. “His experience leading complex rare disease clinical and commercial technical operations, including managing contract manufacturing organizations as well as building internal manufacturing capabilities, will be invaluable as we continue to develop our novel human-derived adeno-associated virus vectors for gene therapy and gene correction.”
Mr. Kelly joins Homology from Sarepta Therapeutics where he served as Head of Technical Operations and was responsible for the process development and manufacturing strategy for Sarepta’s gene therapy programs, and the development, commercialization and scale-up of novel RNA-based chemical therapies. Prior, Mr. Kelly spent eight years at Shire Pharmaceuticals, most recently as Senior Vice President and Head of Biologics Operating Unit, where he was responsible for technical operations for all clinical and commercial biologics and gene therapy products, including internal and external manufacturing. At Shire, Mr. Kelly also served as Interim Head of Technical Operations, Head of Product Strategy & Planning, Head of Global External Operations and Head of Global Supply Chain. He was previously the Head of Technical Operations at UCB in Belgium, with direct management of operations in Belgium, Switzerland, the United Kingdom, Germany, Ireland, Japan and India. Mr. Kelly also held roles of increasing responsibility at Biogen Idec, including Senior Director of International Operations. Mr. Kelly holds a B.S. with emphasis in Engineering Mechanics from the United States Air Force Academy and an M.B.A. from Troy University.
“I have had the opportunity to evaluate and work with many new technologies over the course of my career, and I believe that the Homology gene editing and gene therapy platform represents a truly transformative approach with the potential to cure genetic diseases,” said Mr. Kelly. “I look forward to working with the dedicated team at Homology to build and scale our product development and manufacturing capabilities, enabling us to bring new therapies to patients with rare genetic diseases.”
About Homology Medicines, Inc.
Homology Medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The combination of a new multidimensional technology platform and a management team that has successfully developed and commercialized rare disease therapies uniquely positions the Company to move beyond the current limitations of gene therapy and gene editing approaches to improve patient care. Homology has built foundational intellectual property on gene editing and gene therapy using vectors derived from naturally occurring human adeno-associated viruses (AAVs). The Company’s technology is precise, on-target and highly efficient for in vivo editing of genetic mutations. The unique team and technology create a significant opportunity for Homology to rapidly advance a diverse pipeline of new medicines that address and potentially cure the underlying cause of genetic diseases. For more information, please visit www.homologymedicines.com.